Track Quanterix Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Quanterix Corporation QTRX · Stock Open Quanterix Corporation in new tab

2.93 USD
EPS
-2.34
P/B
0.62
ROE
-41.65
Beta
1.03
Target Price
3.17 USD
Quanterix Corporation logo

Quanterix Corporation

🧾 Earnings Recap – Q1 2026

Quanterix shares dropped 16.7% after earnings as investors reacted negatively to softer-than-expected instrumentation sales and a cautious near-term outlook, despite ongoing investments and operational changes that have yet to deliver clear growth.

  • Q1 revenue totaled $36.4 million, with consumable sales meeting plans but instrumentation revenue coming in below expectations.
  • Management attributed weaker instrument sales partially to timing issues but acknowledged the need for sharper sales focus and commercial investments.
  • The company is increasing investments in leadership and go-to-market capabilities to drive pharma partnerships and new business development.
  • Gross margins and cash usage targets were maintained, reflecting operational discipline despite top-line pressures.
  • Quanterix emphasized long-term growth initiatives, particularly in Alzheimer’s diagnostics, but these remain early-stage without immediate financial impact.
📅
Loading chart...
Key Metrics
Earnings dateMarch 2, 2027
EPS-2.34
Book Value4.62
Price to Book0.62
Debt/Equity14.30
% Insiders6.345%
Growth
Revenue Growth-0.13%
Estimates
Forward P/E-1.99
Forward EPS-1.44
Target Mean Price3.17

DCF valuation

Model fair value for Quanterix Corporation (QTRX)
Result
Sign in to run the valuation for QTRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Hold · mean target 3.17 USD (low 3.00, high 3.50) · as of 12 Nov 2026
Low 3.00
Mean 3.17
High 3.50
Price 2.93
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Quanterix Corporation Logo Quanterix Corporation Analysis (QTRX)

United States Health Care Official Website Stock

Is Quanterix Corporation a good investment? Quanterix Corporation (QTRX) is currently trading at 2.93 USD. Market analysts have a consensus price target of 3.17 USD. This suggests a potential upside from current levels.

Earnings Schedule: Quanterix Corporation is expected to release its next earnings report on March 2, 2027. The market consensus estimate for Forward EPS is -1.44.

Investor FAQ

Does Quanterix Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Quanterix Corporation?

Quanterix Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 2, 2027. The company currently has a trailing EPS of -2.34.

Company Profile

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Exchange Ticker
NGM (Sweden) QTRX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion